Johnson & Johnson says it plans to file 10 new molecular entities - each with the potential of pulling in sales in excess of $1 billion - and 40 line extensions of existing and new medicines by 2019.

Coupled with 14 new product launches since 2009, seven of which are already blockbusters or close to it, the firm says its robust portfolio and late-stage pipeline have placed it in good stead to achieve above-industry compound annual growth over the next four years.

The US healthcare giant noted that the total global branded pharmaceuticals market is expected to grow at a compound annual operational growth rate of around 3% from 2014 to 2019, according to IMS Health data, and that its pharmaceuticals unit is currently growing around 16.5% a year.

“In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines,” said Joaquin Duato, worldwide chairman of Pharmaceuticals at Johnson & Johnson.

Expected near-term growth drivers (after approval) include ‘breakthrough’ multiple myeloma drug daratumumab; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 for urothelial cancer; ‘breakthrough’ esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus; fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C. 

J&J also announced that its Janssen unit is planning to submit a Biologic Licensing Application to regulators on both sides of the Atlantic this year for daratumumab in double refractory multiple myeloma, based on Phase II data which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.